|
|
|
|
Vol. 58, Issue 6, 1230-1238, December 2000
Departments of Receptor Biochemistry (C.W., G.C., P.I., T.K.) and
Molecular Sciences (J.W., W.-J.C.), Glaxo Wellcome Research and
Development, Research Triangle Park, North Carolina
The quantitative comparison of the relative potency of agonists is a
standard method of receptor and agonist classification. If agonist
potency ratios do not correspond in two given tissues, this is used as
presumptive data to conclude that the receptors in those two tissues
are different. This article presents data to show that a single
receptor can demonstrate varying agonist potency ratios in different
host cells. These data are described in terms of the production of more
than one agonist-selective receptor active state and the interaction of
these different active states with multiple G proteins in the membrane
to produce cellular response. Stable host human embryonic kidney 293 cells with enhanced quantities of the respective G
-protein were
created. Wild-type and G
-subunit enriched cells were then
transiently transfected with human calcitonin receptor type 2 (hCTR2).
Binding did not detect differences in the G protein-enriched cells
versus wild-type cells. In contrast, functional studies did show
differences between the host cell lines and G
-subunit enriched cell
lines. The relative potency of eight calcitonin agonists was measured
in studies of calcium fluorescence in transfected cells containing
human calcitonin receptor type 2 by comparing pEC50 (-log
molar concentration producing half-maximal response) values. In
G
s-enriched cells, the relative order of potency of the agonists
changed. The host-cell dependent differences in potency ratios ranged
from 2-fold to more than 46-fold. This finding is not consistent with
the idea that all of the agonists produce response in the same manner
(i.e., through a common active state of the receptor). These data are
consistent with the idea that these different agonists produce arrays
of active states that differentially use G proteins. This idea is discussed in terms of the design of stimulus-bias assay systems to
detect agonist-selective receptor active states with resulting potential for increased selectivity of agonists.
This article has been cited by other articles:
![]() |
L. Stanasila, J.-B. Perez, H. Vogel, and S. Cotecchia Oligomerization of the {alpha}1a- and {alpha}1b-Adrenergic Receptor Subtypes: POTENTIAL IMPLICATIONS IN RECEPTOR INTERNALIZATION J. Biol. Chem., October 10, 2003; 278(41): 40239 - 40251. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Azzi, P. G. Charest, S. Angers, G. Rousseau, T. Kohout, M. Bouvier, and G. Pineyro {beta}-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors PNAS, September 30, 2003; 100(20): 11406 - 11411. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Wei, S. Ahn, S. K. Shenoy, S. S. Karnik, L. Hunyady, L. M. Luttrell, and R. J. Lefkowitz Independent {beta}-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2 PNAS, September 16, 2003; 100(19): 10782 - 10787. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. D. Stout, W. P. Clarke, and K. A. Berg Rapid Desensitization of the Serotonin2C Receptor System: Effector Pathway and Agonist Dependence J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 957 - 962. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Christopoulos and T. Kenakin G Protein-Coupled Receptor Allosterism and Complexing Pharmacol. Rev., June 1, 2002; 54(2): 323 - 374. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Braun, M. Wunderlin, K. Spieth, W. Knochel, P. Gierschik, and B. Moepps Xenopus laevis Stromal Cell-Derived Factor 1: Conservation of Structure and Function During Vertebrate Development J. Immunol., March 1, 2002; 168(5): 2340 - 2347. [Abstract] [Full Text] [PDF] |
||||